Digital Content 
NEWS #PharmaBuzz
07 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/07/3038899/0/en/Arcutis-to-Highlight-Data-from-Phase-3-Trials-for-Scalp-and-Body-Psoriasis-and-Atopic-Dermatitis-at-the-83rd-American-Academy-of-Dermatology-Meeting.html
26 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/26/3032866/0/en/U-S-FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Children-Aged-2-to-5-with-Mild-to-Moderate-Atopic-Dermatitis.html
24 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/24/3031084/0/en/Arcutis-Announces-Publication-of-Positive-Data-from-INTEGUMENT-PED-Trial-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Children-2-to-5-Years-Old-with-Mild-to-Moderate-Atopic-Dermatit.html
21 Feb 2025
// BUSINESS STD
https://www.business-standard.com/markets/news/senores-pharma-rises-6-after-its-arm-inks-agreement-to-acquire-roflumilast-125022100350_1.html
03 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/03/2990547/0/en/Arcutis-Announces-Promotions-on-Executive-Management-Team.html
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980227/0/en/Arcutis-ZORYVE-roflumilast-Awarded-Best-Eczema-Treatment-by-Glamour.html
Share 